PPARG and metabolic dysfunction-associated steatotic liver disease: Its dual role in enhancing fatty acid oxidation and suppressing lipogenesis, coupled with SIRT1‐dependent deacetylation of PPARγ, positions STA as a promising candidate for NAFLD therapy.